Kura Oncology share price today

Kura Oncology, Inc.'s share price was $7.61 at the close on 4 November 2026. That is 22.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $13, and at that close it was at the low of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 1 year the share price moved +21% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Kura Oncology, Inc. pays no dividend. In the last 7 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Kura Oncology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Kura Oncology, Inc. posted a net loss of $68.3 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $279 M. That loss is 327.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost $66.1 M.

Read this profit with care: at −$68.3 M it is bigger than the quarter's whole revenue of $20.9 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −349.8% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

Kura Oncology, Inc. reported $20.9 M of revenue in the Jun 2026 quarter, +36.5% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 1 years it has grown 25.2% a year on average. The last full year, FY25, came in at $67.5 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $77.2 M.

Recent pace: the last four quarters grew −0.6% on average, against 25.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Kura Oncology, Inc.'s operating margin was −349.8% in the Jun 2026 quarter, 125.5 percentage points higher than the same quarter a year ago.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 2 years it has been between −449.9% and −358.5%.

Why the margin moved: operating margin changed +125.5 percentage points on the year while gross margin changed +113.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Kura Oncology, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $64.1 M of cash, against −$279 M of profit. After $6.6 M of spending on assets, free cash was −$70.7 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Kura Oncology, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $7.1 M on assets over the last 2 years. Averaged over those years that is 5.3% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $7.1 M over the last 2 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Kura Oncology, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Kura Oncology, Inc. at 10.0× its FY25 revenue of $67.5 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Kura Oncology, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Kura Oncology, Inc. earned a ROE of −160% in FY25. Its return on capital used (ROIC) is 107.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −412.9% net margin and 0.09× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −412.9% net margin × 0.09× asset turnover × 4.24× leverage (assets divided by equity) ≈ −157.6% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: −99.9% − 7.1% = −107.0 percentage points. The 7.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Kura Oncology, Inc. has total debt of $24.5 M against shareholder equity of $48.4 M as of Jun 2026, so its debt is 0.50× its equity. Year by year, that ratio went from 0.01 in FY21 to 0.12 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

20.3% of Kura Oncology, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Kura Oncology, Inc., the Z-score is −3.02. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of −3.02 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Kura Oncology, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Kura Oncology is the 129th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Geron Corporation, Candel Therapeutics, Inc. and 4D Molecular Therapeutics, Inc. Just below it: Zevra Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and SL Science Holding.

Biotechnology companies close in size

126. Geron Corporation $694 million
127. Candel Therapeutics, Inc. $692 million
128. 4D Molecular Therapeutics, Inc. $678 million
129. Kura Oncology, Inc. $677 million
130. Zevra Therapeutics, Inc. $665 million
131. Lexicon Pharmaceuticals, Inc. $659 million
132. SL Science Holding Limited $633 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2694. HMH Holding Inc. $678 million · Oil & Gas Equipment & Services
2695. Super Hi International Holding Ltd. $678 million · Restaurants
2696. Kura Oncology, Inc. $677 million
2697. Third Coast Bancshares, Inc. $676 million · Banks - Regional
2698. Jumia Technologies AG $676 million · Internet Retail

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.